Immunovia AB: A Focus on Cancer Diagnosis and Monitoring
Immunovia AB, a company based in Lund, Sweden, operates within the health care sector, specifically in the health care equipment and supplies industry. The company is listed on the Swedish Stock Exchange and trades in SEK. As of August 25, 2025, Immunovia’s close price was recorded at 0.96 SEK, with a market capitalization of 227,420,000 SEK.
The company specializes in the development and manufacturing of bioinformatic devices designed to aid in the diagnosis of cancer, predict disease progression, and monitor the therapeutic responsiveness of cancers. These innovative solutions are tailored to meet the needs of healthcare providers, enhancing their ability to deliver precise and effective cancer care.
Immunovia AB serves its client base exclusively within Sweden, focusing on providing advanced diagnostic tools to improve patient outcomes in the country. The company’s commitment to innovation in cancer diagnostics positions it as a key player in the Swedish healthcare landscape.
Financially, Immunovia has experienced fluctuations in its stock price over the past year. The 52-week high was reached on September 17, 2024, at 1.31 SEK, while the 52-week low was recorded on April 6, 2025, at 0.244 SEK. The company’s price-to-earnings ratio stands at -0.781, reflecting its current financial performance and market valuation.
As Immunovia continues to advance its technology and expand its offerings, it remains dedicated to supporting healthcare professionals in Sweden with cutting-edge tools for cancer diagnosis and management.